Takeaway

• Patients with advanced NSCLC who happen to be concurrently taking antidiabetic medications (metformin alone or with dipeptidyl peptidase 4 [DPP4] inhibitor) show greater benefit with immune checkpoint inhibitors (ICIs).
• Their objective response rate (ORR) is higher, and their PFS is longer than those only taking ICIs.

Why this matters

• Preclinical studies...